Literature DB >> 11734101

Epilepsy in Aging Populations.

Mercedes P. Jacobson1.   

Abstract

Older adults pose special challenges when seizures or epilepsy occur. Increased risk for seizures is often unrecognized. Older adults may have milder epilepsy, and may not require or tolerate standard doses of anti-epileptic drugs (AEDs). Polypharmacy and drug interactions are potential problems, and altered protein binding, hepatic function, renal clearance, and gastric function can affect AED dosing. Side effects such as ataxia, somnolence, and confusion are of heightened concern in this group. Older adults typically suffer localization or focal onset seizures. Although many AEDs treat these types of seizures, the AED chosen for any given patient is determined by concomitant polypharmacy, side effect profile, as well as underlying medical conditions. Free and total AED levels may be necessary. The goal of seizure management for a hospitalized patient may be rapid seizure control. As the individual moves into the outpatient setting, AED therapy without side effects and with appropriate quality of life must be pursued.

Entities:  

Year:  2002        PMID: 11734101     DOI: 10.1007/s11940-002-0002-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  31 in total

1.  Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  M J Glantz; B F Cole; P A Forsyth; L D Recht; P Y Wen; M C Chamberlain; S A Grossman; J G Cairncross
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Anticonvulsant osteomalacia in epileptic outpatients.

Authors:  V Hoikka; K Savolainen; E M Alhava; J Sivenius; P Karjalainen; M Parvianinen
Journal:  Ann Clin Res       Date:  1982-06

3.  The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy.

Authors:  S Snel; J A Jansen; H B Mengel; A Richens; S Larsen
Journal:  J Clin Pharmacol       Date:  1997-11       Impact factor: 3.126

4.  The disposition of primidone in elderly patients.

Authors:  C Martines; G Gatti; E Sasso; S Calzetti; E Perucca
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

5.  Incidence and prognostic significance of "epileptiform" activity in the eeg of non-epileptic subjects.

Authors:  L Zivin; C A Marsan
Journal:  Brain       Date:  1968       Impact factor: 13.501

6.  A survey of epileptic disorders in southwest France: seizures in elderly patients.

Authors:  J Loiseau; P Loiseau; B Duché; M Guyot; J F Dartigues; B Aublet
Journal:  Ann Neurol       Date:  1990-03       Impact factor: 10.422

7.  Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.

Authors:  R H Mattson; J A Cramer; J F Collins; D B Smith; A V Delgado-Escueta; T R Browne; P D Williamson; D M Treiman; J O McNamara; C B McCutchen
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

8.  Incidence and clinical characterization of unprovoked seizures in adults: a prospective population-based study.

Authors:  L Forsgren; G Bucht; S Eriksson; L Bergmark
Journal:  Epilepsia       Date:  1996-03       Impact factor: 5.864

9.  Risk factors for developing seizures after a stroke.

Authors:  M E Lancman; A Golimstok; J Norscini; R Granillo
Journal:  Epilepsia       Date:  1993 Jan-Feb       Impact factor: 5.864

10.  Dementia and adult-onset unprovoked seizures.

Authors:  D C Hesdorffer; W A Hauser; J F Annegers; E Kokmen; W A Rocca
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

View more
  1 in total

1.  In silico design of novel probes for the atypical opioid receptor MRGPRX2.

Authors:  Katherine Lansu; Joel Karpiak; Jing Liu; Xi-Ping Huang; John D McCorvy; Wesley K Kroeze; Tao Che; Hiroshi Nagase; Frank I Carroll; Jian Jin; Brian K Shoichet; Bryan L Roth
Journal:  Nat Chem Biol       Date:  2017-03-13       Impact factor: 15.040

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.